Kilonzo Semvua B, Gunda Daniel W, Kashasha Flora, Mpondo Bonaventura C
Department of Medicine, Catholic University of Health and Allied Sciences, P.O. Box 1464, Mwanza, Tanzania.
Department of Medicine, Bugando Medical Centre, P.O. Box 1370, Mwanza, Tanzania.
J Trop Med. 2017;2017:5629130. doi: 10.1155/2017/5629130. Epub 2017 Jul 30.
Liver fibrosis which is a common complication of chronic hepatitis B infection is rarely diagnosed in low-resource countries due to limited capacity to perform biopsy studies. Data on the utilization of noninvasive techniques which are feasible for diagnosis of liver fibrosis in these settings among HIV-infected patients is scarce. The objective of this study was to establish the magnitude of liver fibrosis by using both aspartate-aminotransferase-to-platelets ratio and fibrosis-4 scores with associated hepatitis B coinfection among antiretroviral therapy naïve HIV-infected patients.
We reviewed data of 743 adult patients attending HIV clinic with available hepatitis B surface antigen test results. Baseline clinical information was recorded and aspartate-aminotransferase-to-platelet ratio and fibrosis-4 scores were calculated. The cut-off values of 1.5 and 3.25 were used for diagnosis of significant fibrosis by aspartate-aminotransferase-to-platelets ratio and fibrosis-4 scores, respectively.
The prevalence of liver fibrosis was 3.5% when aspartate-aminotransferase-to-platelet score was used and 4.6% with fibrosis-4 score and they were both significantly higher among patients with hepatitis B coinfection. Younger patients with HIV advanced disease and elevated liver transaminases had increased risk of having hepatitis B coinfection.
A remarkable number of HIV-infected patients present with liver fibrosis, predominantly those with hepatitis B infection.
肝纤维化是慢性乙型肝炎感染的常见并发症,在资源匮乏的国家,由于进行活检研究的能力有限,很少能得到诊断。在这些环境中,关于在艾滋病毒感染患者中使用可行的非侵入性技术诊断肝纤维化的数据很少。本研究的目的是通过使用天冬氨酸氨基转移酶与血小板比值(APRI)和纤维化-4(FIB-4)评分来确定初治抗逆转录病毒治疗的艾滋病毒感染患者中肝纤维化的程度以及相关的乙型肝炎合并感染情况。
我们回顾了743名到艾滋病毒诊所就诊且有可用乙型肝炎表面抗原检测结果的成年患者的数据。记录基线临床信息,并计算天冬氨酸氨基转移酶与血小板比值和纤维化-4评分。APRI和FIB-4评分分别采用1.5和3.25的临界值来诊断显著纤维化。
使用APRI评分时肝纤维化的患病率为3.5%,使用FIB-4评分时为4.6%,在乙型肝炎合并感染患者中两者均显著更高。艾滋病毒晚期疾病且肝转氨酶升高的年轻患者发生乙型肝炎合并感染的风险增加。
相当数量的艾滋病毒感染患者存在肝纤维化,主要是那些合并乙型肝炎感染的患者。